The lockdown has worked very well, so those who were infected earlier are getting discharged, or are getting well on their own. I suppose the BCG vaccine has also played its part.
The only reason why our numbers looks so high is because of the Jamaatis screwing things up.
A danda by Delhi Police and Khujliwal administration would have done the job
Khujli is scared to even call these guy by name and you expect him to take any action against them.
Atleast Khujli is reporting the Markaz cases separately , calling them Special
Operations
Mumbai has not given any data on NCP
Pressure
Yeah because bihar, up and west bengal were kept underdeveloped so that India can get cheap labour
. This is actually a part of India's economic policy. We have to compromise something to achieve that.
Most chutiya chief minister is Uddhav Thakre. Now Bandra station is full of migrants labourers. They have failed to communicate about extension of lockdown.
Yeah because bihar, up and west bengal were kept underdeveloped so that India can get cheap labour
If UP and Bihar are where they are it is
Because of Crime , corruption and casteism
Bengal has been ruined by communism
Bihar was growing before lalu, but then after 91 India needed the labour and Bihar, UP, WB, Odisha, were important states to supply labours. They neglected all these states intentionally for the need of growing demand. It was all planned.
Drug, medical device manufacturing companies operate at 50% capacity
Last Updated: Apr 14, 2020, 10.51 AM IST
By Rupali Mukherjee
With units still limping back to normalcy across the country and inventory levels running low, there could be shortages ahead of certain essential medicines and devices, companies say.
To make matters worse, prices of active pharmaceutical ingredients (APIs) have increased with delays in imports, though shipments from certain areas in China have resumed.
MUMBAI: Prospects of a steady supply of medicines and devices are yet to improve. Drug manufacturing plants and medical device units continue to face disruptions on account of an interrupted supply chain of key raw materials and packaging, as well as employee commuting problems due to the national lockdown. Average capacity utilisation is at a low 40-50%.
With units still limping back to normalcy across the country and inventory levels running low, there could be shortages ahead of certain essential medicines and devices, companies say. A GSK executive told TOI, though certain bottlenecks have eased, issues remain with regard to suppliers and contract manufacturing units, which continue to face employee movement-related challenges in Daman.
The executive added truckers’ movement through inter-state borders remains problematic but the Nashik-based plant does not have any worker issues as they are based locally. “The plant is currently operating at full capacity. However, there are challenges with the supply chain and particularly ensuring material flows into the factory uninterrupted. Some part of our production might get hampered as suppliers are not providing packaging,” he said.
Medical device companies, which import key components or need to transport them across India, are still facing delays with shipments (air and sea cargo), and with local couriers and transporters. “Companies are limping back to a limited capacity in some areas, with 30-40% of pre-lockdown production levels and 20-30% for dispatch levels. Units at containment and sealed areas are effectively shut as movement of workers and vehicles has stopped. Logistics is improving slowly,” said Rajiv Nath, forum coordinator of AiMeD, an industry association of domestic medical devices companies. Chennai-based Trivitron Healthcare and others have flagged issues related to movement of key components, transportation of finished goods, and delays in import shipments of Covid-testing kits. Units that manufacture key raw materials and packaging material are still facing a lockdown. Hence their supplies are affected. “We are managing with inventory, which will last for a couple of weeks only,” a Mumbai-based drug company said.
To make matters worse, prices of active pharmaceutical ingredients (APIs) have increased with delays in imports, though shipments from certain areas in China have resumed. “Production levels vary and, except for a few plants where attendance was low due to restrictions on inter-state people movement, our operations have not been majorly impacted. We are grateful to the government authorities for their continued support to the pharmaceuticals industry. Things are getting better and we hope to get more support from transport providers and the pharmaceutical ancillary units. The health and safety of employees remain our top priority,” a spokesperson from Mumbai-based Sun Pharma, which has plants at over 20 different locations, said.
However, according to data from pharma research firm Aiocd-Awacs, there is adequate stock at distributor level across therapies, with the least in anti-diabetics (four weeks) and highest in dermatology (eight weeks). Overall, there’s an inventory of 52 days for anti-malarials like hydroxychloroquine (HCQ), despite the spurt in sales. As production and transport ramps up, stock levels are expected to go up and stabilise, preventing any shortages of essential medicines. Overall, there are stocks of almost three months.
Drug, medical device manufacturing companies operate at 50% capacity
Last Updated: Apr 14, 2020, 10.51 AM IST
By Rupali Mukherjee
With units still limping back to normalcy across the country and inventory levels running low, there could be shortages ahead of certain essential medicines and devices, companies say.
To make matters worse, prices of active pharmaceutical ingredients (APIs) have increased with delays in imports, though shipments from certain areas in China have resumed.
MUMBAI: Prospects of a steady supply of medicines and devices are yet to improve. Drug manufacturing plants and medical device units continue to face disruptions on account of an interrupted supply chain of key raw materials and packaging, as well as employee commuting problems due to the national lockdown. Average capacity utilisation is at a low 40-50%.
With units still limping back to normalcy across the country and inventory levels running low, there could be shortages ahead of certain essential medicines and devices, companies say. A GSK executive told TOI, though certain bottlenecks have eased, issues remain with regard to suppliers and contract manufacturing units, which continue to face employee movement-related challenges in Daman.
The executive added truckers’ movement through inter-state borders remains problematic but the Nashik-based plant does not have any worker issues as they are based locally. “The plant is currently operating at full capacity. However, there are challenges with the supply chain and particularly ensuring material flows into the factory uninterrupted. Some part of our production might get hampered as suppliers are not providing packaging,” he said.
Medical device companies, which import key components or need to transport them across India, are still facing delays with shipments (air and sea cargo), and with local couriers and transporters. “Companies are limping back to a limited capacity in some areas, with 30-40% of pre-lockdown production levels and 20-30% for dispatch levels. Units at containment and sealed areas are effectively shut as movement of workers and vehicles has stopped. Logistics is improving slowly,” said Rajiv Nath, forum coordinator of AiMeD, an industry association of domestic medical devices companies. Chennai-based Trivitron Healthcare and others have flagged issues related to movement of key components, transportation of finished goods, and delays in import shipments of Covid-testing kits. Units that manufacture key raw materials and packaging material are still facing a lockdown. Hence their supplies are affected. “We are managing with inventory, which will last for a couple of weeks only,” a Mumbai-based drug company said.
To make matters worse, prices of active pharmaceutical ingredients (APIs) have increased with delays in imports, though shipments from certain areas in China have resumed. “Production levels vary and, except for a few plants where attendance was low due to restrictions on inter-state people movement, our operations have not been majorly impacted. We are grateful to the government authorities for their continued support to the pharmaceuticals industry. Things are getting better and we hope to get more support from transport providers and the pharmaceutical ancillary units. The health and safety of employees remain our top priority,” a spokesperson from Mumbai-based Sun Pharma, which has plants at over 20 different locations, said.
However, according to data from pharma research firm Aiocd-Awacs, there is adequate stock at distributor level across therapies, with the least in anti-diabetics (four weeks) and highest in dermatology (eight weeks). Overall, there’s an inventory of 52 days for anti-malarials like hydroxychloroquine (HCQ), despite the spurt in sales. As production and transport ramps up, stock levels are expected to go up and stabilise, preventing any shortages of essential medicines. Overall, there are stocks of almost three months.
Drug, medical device manufacturing companies operate at 50% capacity
Not "Migrants", but locals who are native of other states, especially Uttar Pradesh & Bihar.
Mostly locals(almost all people here are native of other states) from nearby slums located on eastern part of Bandra local station, around east south general direction from Bandra Terminus. Important to note, people located near Bandra Terminus crossed Bandra local station and converged in front of Mosque, adjacant to Bandra Local station western side. Outstation trains run from eastern side Bandra Terminus, not western side Bandra Local Station.
It's not one person's doing, rather we believe it spread in specific homes and that can be only done by collective efforts. Political chess is already in motion.